Long-Acting HIV Treatment in People with HIV-1 Subtype A6 and Others

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, retrospective observational study uses medical records from treatment centers in Poland, Germany, and the Czech Republic to evaluate the real-world effectiveness and safety of long-acting cabotegravir plus rilpivirine (CAB/RPV LA) in adults with HIV-1. Participants are grouped by HIV-1 subtype (A6, B, unknown) and analyzed for virologic outcomes, treatment persistence, and adherence over 24 months. Subtype A6 cases are matched to subtype B controls using propensity scores to reduce confounding, while unknown subtypes are analyzed separately. Data collection spans initiation and follow-up visits at roughly 6, 12, 18, and 24 months, with proviral DNA genotyping performed for unknown subtypes as an exploratory step. The study relies on routinely collected clinical data from electronic and paper records and aims to illuminate real-world performance of CAB/RPV LA across subtypes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of HIV-1 infection
* Age ≥18 years at the time of initiation of long-acting cabotegravir plus rilpivirine (CAB/RPV LA)
* Received at least one dose of CAB/RPV LA as part of routine clinical care
* Availability of relevant clinical data in medical records for retrospective analysis
* Signed informed consent for use of clinical data
* Agreement to provide an additional blood sample for proviral DNA genotyping, if HIV-1 subtype was unknown at treatment initiation

Exclusion Criteria:

\- Lack of patient consent for use of clinical data for research purposes

Where it's running

• Hospital Na Bulovce Praque HIV Centre, Department of Infectious Diseases
  Prague, Czechia Recruiting
• MainFachArzt
  Frankfurt, Germany Recruiting
• Wojewódzki Szpital Obserwacyjno-Zakaźny
  Bydgoszcz, Poland Recruiting
• Szpitale Pomorskie
  Gdansk, Poland Recruiting
• Wojewódzki Szpital Zakaźny w Warszawie
  Warsaw, Poland Recruiting
• Wrocławskie Centrum Zdrowia
  Wroclaw, Poland Recruiting

Study contacts

• Study coordinator: Miłosz Parczewski, prof. dr hab. n. med.
• Email: klinzak@pum.edu.pl
• Phone: +48 91 813 94 41

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Preventing cervical cancer in women with HPV and HIV in Karnataka, India

  This trial will test whether a six-month ASHA-Health program of group education, ASHA-supported one-on-one sessions, nutrition support, and life-skills training can reduce persistent high-risk HPV in women living with HIV.

  Recruiting at 3 sites University of California, Irvine · Bangalore, Karnataka and 3 other locations · NCT07209917

• Improving HIV treatment options for youth

  This study is testing if personalized treatment options and counseling can help young people with HIV better manage their condition and improve their health.

  Recruiting Johns Hopkins University · Baltimore, Maryland · NCT06886971

• Doravirine treatment for HIV-infected children under 12 years old

  This study is testing a new HIV treatment called doravirine in children under 12 to see if it's safe and effective for them.

  Recruiting at 13 sites Phase 2 Merck Sharp & Dohme LLC · Aurora, Colorado and 25 other locations · NCT04375800

• Once-weekly islatravir plus ulonivirine for people with untreated HIV-1

  This trial tests whether a once-weekly oral combination of islatravir and ulonivirine can control HIV-1 in people who have never taken antiretroviral therapy.

  Recruiting at 53 sites Phase 2/3 Merck Sharp & Dohme LLC · Los Angeles, California and 55 other locations · NCT07266831

• Pregnant Women Living with HIV on Bictegravir/Emtricitabine/Tenofovir Alafenamide

  This study looks at how B/F/TAF is used in pregnant women with HIV and whether it helps maintain viral suppression from before conception through delivery.

  Recruiting Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · Paris · NCT07921472

• Multiple interventions to try for HIV remission in people on ART

  This study tests a combination approach, including intensified ART, latency-reversal agents, and autologous dendritic cell therapy, to see if people living with HIV on long-term ART can achieve sustained viral suppression or prolonged remission.

  Recruiting Phase 2 Federal University of São Paulo · São Paulo, São Paulo · NCT07903441

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.